Stockscreener 앱 받기
4.56
5.39%
-0.26
Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스
Armata Pharmaceuticals, Inc. Revenue Breakdown – AMEX:ARMP - TradingView
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Is Armata Pharmaceuticals Inc (ARMP) Facing Challenges After Q2 - GuruFocus
Armata Pharmaceuticals, Inc. 2026: Revenue $2.51M, Net income $74.14M, EPS ($0.27) — 10-Q Summary - TradingView
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update - PR Newswire
Armata Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ARMP) - TradingView
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Net Loss Wide of Estimates, Cash Burn Remains a Focus - dars.gov.et
ARMP|Armata Pharmaceuticals Inc|Price:5.150|Chg%:+0.490 - TradingKey
Armata Pharmaceuticals Inc - TradingKey
Armata Pharmaceuticals Inc (ARMP) Cash Flow - TradingKey
TradingKey - TradingKey
Armata Pharmaceuticals Inc (ARMP) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
ARMP|Armata Pharmaceuticals Inc|Price:4.650|Chg%:-0.570 - TradingKey
Armata Pharmaceuticals Inc (ARMP) Institutional Confidence - TradingKey
Daniel B. Gilmer Net Worth (2026) - GuruFocus
Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history - Yahoo Finance Singapore
Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - Yahoo! Finance Canada
Armata Pharmaceuticals (ARMP) Advances Towards Phase 3 Study for AP-SA02 - GuruFocus
Armata Pharmaceuticals (ARMP) Advances Superbug Therapy, Stock R - GuruFocus
Armata (ARMP) Names David House as New CFO to Lead Financial Str - GuruFocus
Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug Treatment - Moomoo
Armata submits Phase 3 protocol for antibiotic-resistant drug By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Names David House as CFO; Advances Staphylococcus Aureus Treatment Candidate - Moomoo
Why Is Armata Pharma Stock Gaining Monday? - Benzinga
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 - Morningstar
Armata Advances AP-SA02 Toward Phase 3 Trial Launch - TipRanks
Armata Pharmaceuticals Promotes David House to CFO - TipRanks
Armata submits Phase 3 protocol for antibiotic-resistant drug - Investing.com
Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything (NYSE:ARMP) - Seeking Alpha
Form 4 Armata Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals (ARMP) CEO reports tax withholding of 14,041 shares - Stock Titan
Armata Pharmaceuticals, Inc. (ARMP) has received acceptance from the U.S. Food and Drug Administration (FDA) on its initial pediatric study plan for AP-SA02 for the treatment of complicated Staphylococcus aureus bacteremia. - Bitget
Armata receives FDA agreement on pediatric study plan for AP-SA02 - Investing.com UK
Armata Advances AP-SA02 Pediatric Plan With FDA Agreement - TipRanks
Armata Pharmaceuticals (ARMP) Secures FDA Agreement for Pediatri - GuruFocus
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals (ARMP) Trades Slightly Lower as Price Nears Key SupportETF Liquidity - DonanımHaber
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2500 Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2000 Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000E Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000E Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Completeness Index - marketscreener.com
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – DUS:TG1N - TradingView
Price to earnings forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Price to earnings forward of Armata Pharmaceuticals, Inc. – DUS:TG1N - TradingView
Price to book forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Enterprise value to EBIT forward of Armata Pharmaceuticals, Inc. – DUS:TG1N - TradingView
Price to sales forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Price to book forward of Armata Pharmaceuticals, Inc. – BOATS:ARMP - TradingView
Enterprise value to revenue forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – BOATS:ARMP - TradingView
ARMP Forecast — Price Target — Prediction for 2027 - TradingView
Armata Pharmaceuticals, Inc. Actuals & Estimates (DUS:TG1N) - TradingView
Armata Pharmaceuticals, Inc. Actuals & Estimates (MUN:TG1N) - TradingView
0.52%
0.07%
자본화:
|
볼륨(24시간):